Culture media

Cell Culture Media Market Worth $14.64 Billion by 2029

Meticulous Market Research Pvt. ltd.

Cell Culture Media Market by Product (Serum-Free, Chemically Defined, Conventional, Xeno-Free/Animal-Free), Application (Monoclonal Antibodies, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic) ) – Global Forecast to 2029

Redding, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — According to a new market research report, Cell Culture Media Market By Product (Serum-Free, Chemically Defined, Conventional, Xeno-Free/Animal-Free), Application (Monoclonal Antibody, Diagnostics, Cancer & Stem Cell Research), End User (Pharma & Biotech, Academic) – Forecast to 2029”, published by Meticulous Research®Cell Culture Media Market is expected to grow at a CAGR of 13.2% from 2022 to 2029 to reach USD 14.64 Billion by 2029.

Download Free Sample Report Now @

Cell culture media, also called growth media, are any gel or liquid created to support cell growth in an artificial environment. When scientists take cells, organs or tissues from living beings, they must preserve them in an appropriate artificial environment. Cell culture media contain compounds needed to support and regulate cell growth. These cells are used in the production of biopharmaceuticals or for research purposes. Growing demand for monoclonal bodies, increasing funding for cell research, and rising R&D expenditure in the life science industry are some of the factors driving the cell culture media market.

Impact of the COVID-19 pandemic: cell culture media market

During the pandemic, major pharmaceutical and biotech companies collaborated to find vaccines and treatment methods to contain the virus. The idea behind the collaboration was to come together and find a solution as quickly as possible during the pandemic. Collaborations have also taken place between companies and universities to speed up the research and production process. The outsourcing of pharmaceutical and biotechnology research to contract research organizations (CROs) has also increased during the pandemic. Here are some examples,

  • In 2022, GSK plc (UK) and Vir Biotechnology, Inc. (US) announced the supply of sotrovimab in the US for the early treatment of COVID-19. Sotrovimab, a monoclonal antibody, was granted Emergency Use Authorization (EUA) by the US FDA in May 2021.

  • In May 2020, four CROs, including Charnwood Molecular LTD (UK), Reach Separations (UK), XenoGesis (UK) and Aurelia Bioscience Ltd (UK), set up a joint initiative to pursue their therapeutic research activity on COVID-19.

  • In April 2020, AstraZeneca plc (UK) and Oxford Biomedica plc (UK) announced an agreement for the worldwide development and distribution of Oxford’s potential recombinant adenoviral vaccine.

  • In March 2020, Eli Lilly and Company (USA) collaborated with AbCellera Biologics Inc. (Canada) on a COVID-19 antibody treatment. Both companies have used AbCellera’s pandemic rapid response platform to develop and manufacture therapeutic antibodies.

  • In March 2020, Mount Sinai Health System (USA) and Harbor BioMed (Hong Kong) signed a multi-year collaboration and used the H2L2 Harbor Mice platform to develop antibodies against SARS-CoV-2.

Speak to our analysts to understand the impact of COVID-19 on your business:

The global cell culture media market is segmented on the basis of product (serum-free medium, chemically defined medium, classical medium, medium without animal component and other cell culture media), application [bioproduction (monoclonal antibody production, therapeutic protein production, vaccine production, and cell & gene therapy)], diagnostics, cancer research, drug screening and development and stem cell research), end user (pharmaceutical and biotechnology companies, academic and research institutes and diagnostic laboratories) and geography. The study also assesses industry competitors and analyzes regional and national markets.

Based on the product, in 2022, it is estimated that the serum-free media segment will account for the largest share of the cell culture media market. The major factor contributing to the large share of this segment is the increased use of cell culture techniques in companies and research institutes, which require media to grow cells. Some of the major benefits offered by this medium include reduced risk of serum agents and increased cell culture productivity. Several serum-free media have been developed and are generally formulated to support the culture of a single cell type. The segment is also expected to grow at the highest CAGR over the forecast period.

Based on the applications, the biomanufacturing segment is expected to grow at the highest CAGR during the forecast period. The increased production of biotherapeutic products for the treatment of diseases such as cancer, diabetes, rheumatoid arthritis and other non-communicable diseases has created an unprecedented demand for cell culture media, which in turn is expected to drive the growth of this segment over the forecast period. .

On the basis of end-user, the pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The main contributing factor is the growing demand for emerging therapeutic antibodies and biosimilars in the coming years.

Quick buy – Cell Culture Media Market Research Report:

Geographically, North America is estimated to dominate the global cell culture media market in 2022, followed by Europe and Asia-Pacific. Increased demand for cellular diagnostics and treatments, presence of major players, availability of skilled professionals, and presence of major research institutes are the major factors contributing to the large regional market share. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Growth is attributed to increasing technological advancements in biotech and pharmaceutical centers, increased focus on vaccine development and clinical research activities, presence of large research organizations, low manufacturing and labor costs -work and the development of health infrastructures.

The report also includes an in-depth assessment of the product portfolio, geographical analysis and key strategic developments adopted by the leading market players of the sector during the period 2019-2022. In recent years, the cell culture media market has witnessed several new product launches, partnerships, agreements and collaborations, expansions and acquisitions. For example, in January 2022, Cytiva (USA) signed an agreement with Nucleus Biologics, LLC (USA) to develop personalized cell media for cell and gene therapies. Additionally, in November 2021, Sartorius AG (Germany) opened its Cell Culture Technology Center in Germany.

Some of the major players operating in this market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), PromoCell GmbH (Germany), Cytiva (US), Lonza Group Ltd (Switzerland), Corning Incorporated (US United States), Becton, Dickinson and Company (United States), HiMedia Laboratories (India), Sartorius AG (Germany), FUJIFILM Holdings Corporation (Japan), Agilent Technologies, Inc. (United States), Miltenyi Biotec BV & Co KG (Germany), BIOLOGOS (USA), STEMCELL Technologies Inc. (Canada) and Cell Applications, Inc. (USA).
For more information on the market with a table of contents and detailed figures, click here:

Report Scope:

Cell Culture Media Market, By Product

Cell Culture Media Market, By Application

Cell Culture Media Market, By End User

Cell Culture Media Market, By Geography

  • North America

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe (RoE)

  • Asia-Pacific (APAC)

    • China

    • Japan

    • India

    • Rest of APAC (RoAPAC)

  • Latin America

  • Middle East and Africa

Download Free Sample Report Now @

Related reports:

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, Cell Lines), Equipment (Bioreactor, Centrifuge, Cell Counter)]Application (Biomanufacturing, Cancer Research, Stem Cells, Diagnostics), End User (Pharma, Academic)—Global Forecast to 2029

In Vitro Toxicology/Toxicity Testing Market by Product & Service, Technology (Cell Culture, OMICS), Method (Cell Assays, In Silico), Endpoint (ADME, Genotoxicity, Organ Toxicity, Skin Toxicity), End-User, and Geography – Global forecasts until 2025

Cell Isolation/Cell Separation Market By Product (Reagents, Beads, Media, Disposables, Centrifuge, Filtration System), Cell Type (Human, Animal), Technology (Filtration, Surface Marker), Application (Research, Therapeutics) ), End User – Global Forecast to 2024

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. ltd. in 2013 as a limited liability company under the Companies Act of 1956. Since its incorporation, the company has become the leading provider of premium business information in North America, Europe, Asia-Pacific , Latin America, the Middle East and Africa. .

Our company name defines our services, our strengths and our values. From the beginning, we have only thrived on researching, analyzing and presenting critical market data with great attention to detail. Through meticulous primary and secondary research techniques, we have developed strong data collection, interpretation and analysis skills, including qualitative and quantitative research with the best team of analysts. We design our intelligent, value-driven, meticulously analyzed union market research reports, custom studies, fast turnaround research, and consulting solutions to address the business challenges of sustainable growth.

Mr. Khushal Bomb
Meticulous Market Research Inc.
1267 Willis Street, Suite 200 Redding,
California, 96001, USA
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
E-mail- [email protected]
Visit our website:
Join us on LinkedIn-
Source of content:

CONTACT: Mr. Khushal Bombe Meticulous Market Research Inc. Direct Lines: +1-646-781-8004 (North America) +44-203-868-8738 (Europe) +91 744-7780008 (Asia-Pacific) Email- [email protected] Visit Our Website: Meticulous Research® Blog: Connect with us on LinkedIn-